iPSC-Derived Dopamine Neurons

iPSC-Derived Dopamine Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Dopamine Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Stem Cell-Derived Neurons</td>
</tr>
<tr>
<td class="label">Origin</td>
<td>Induced Pluripotent Stem Cells</td>
</tr>
<tr>
<td class="label">Target Region</td>
<td>Ventral Midbrain</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>Dopamine</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>TH, AADC, FOXA2, LMX1A, EN1</td>
</tr>
<tr>
<td class="label"> subtype</td>
<td>A9 (Substantia Nigra pars compacta)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Allen Brain Cell Atlas</td>
<td>[Search](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[Search](https://www.ebi.ac.uk/ols4/ontologies/cl/)</td>
</tr>
<tr>
<td class="label">Human Cell Atlas</td>
<td>[Search](https://www.humancellatlas.org/)</td>
</tr>
<tr>
<td class="label">CellxGene Census</td>
<td>[Search](https://cellxgene.cziscience.com/)</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>iPSC-Derived</td>
</tr>
<tr>
<td class="label">Availability</td>
<td>Unlimited</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Tumor risk</td>

iPSC-Derived Dopamine Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">iPSC-Derived Dopamine Neurons</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Stem Cell-Derived Neurons</td>
</tr>
<tr>
<td class="label">Origin</td>
<td>Induced Pluripotent Stem Cells</td>
</tr>
<tr>
<td class="label">Target Region</td>
<td>Ventral Midbrain</td>
</tr>
<tr>
<td class="label">Neurotransmitter</td>
<td>Dopamine</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>TH, AADC, FOXA2, LMX1A, EN1</td>
</tr>
<tr>
<td class="label"> subtype</td>
<td>A9 (Substantia Nigra pars compacta)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Allen Brain Cell Atlas</td>
<td>[Search](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[Search](https://www.ebi.ac.uk/ols4/ontologies/cl/)</td>
</tr>
<tr>
<td class="label">Human Cell Atlas</td>
<td>[Search](https://www.humancellatlas.org/)</td>
</tr>
<tr>
<td class="label">CellxGene Census</td>
<td>[Search](https://cellxgene.cziscience.com/)</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>iPSC-Derived</td>
</tr>
<tr>
<td class="label">Availability</td>
<td>Unlimited</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Tumor risk</td>
<td>Low with purification</td>
</tr>
<tr>
<td class="label">Ethical concerns</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Patient-specific</td>
<td>Yes</td>
</tr>
</table>

Ipsc Derived Dopamine Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Induced pluripotent stem cell (iPSC)-derived dopamine neurons are midbrain dopaminergic neurons generated from patient-derived or healthy donor-derived iPSCs. These neurons hold tremendous promise for Parkinson's disease cell replacement therapy, disease modeling, and drug screening applications. iPSC technology allows for the generation of patient-specific dopamine neurons that can be transplanted autologously or used for in vitro disease modeling["@kriks2011"][@takahashi2006].

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [Cell Ontology](https://www.ebi.ac.uk/ols4/ontologies/cl/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [PanglaoDB](https://panglaodb.se/)

Differentiation Protocols

Floor Plate Method

The most widely used protocol involves directing iPSC differentiation toward a floor plate fate, which gives rise to ventral midbrain dopaminergic neurons:

Key Growth Factors

• SHH (Sonic Hedgehog): Patterns ventral midbrain fate
• FGF8 (Fibroblast Growth Factor 8): Rostral patterning
• BDNF (Brain-Derived Neurotrophic Factor): Neuronal survival
• GDNF (Glial Cell Line-Derived Neurotrophic Factor): Dopaminergic neuron maintenance
• Ascorbic Acid: Promotes dopaminergic differentiation
• cAMP: Enhances dopamine synthesis

Molecular Characterization

Dopaminergic Markers

• Tyrosine Hydroxylase (TH): Rate-limiting enzyme in dopamine synthesis
• Aromatic L-Amino Acid Decarboxylase (AADC): Converts L-DOPA to dopamine
• Vesicular Monoamine Transporter 2 (VMAT2): Dopamine packaging
• Dopamine Transporter (DAT): Dopamine reuptake

Transcription Factors

• FOXA2: Forkhead box A2, essential for midbrain patterning
• LMX1A/LMX1B: LIM homeobox transcription factor 1
• EN1/EN2: Engrailed homeobox 1/2
• OTX2: Orthodenticle homeobox 2
• NR4A2 (Nurr1): Nuclear receptor related 1, crucial for dopaminergic identity

Disease Modeling Applications

Parkinson's Disease Modeling

iPSC-derived dopamine neurons from PD patients provide unprecedented insights into disease mechanisms:

• LRRK2 G2019S mutations: Leading genetic cause of PD, shows increased alpha-synuclein aggregation
• GBA mutations: Associated with earlier onset and cognitive decline
• PINK1 mutations: Reveals mitochondrial dysfunction in dopaminergic neurons
• SNCA mutations: Direct insights into alpha-synuclein pathology

Drug Screening Platforms

iPSC-derived neurons enable high-throughput screening:

• Neuroprotective compounds: Identify drugs that prevent dopaminergic degeneration
• Alpha-synuclein aggregation inhibitors: Target pathological protein aggregation
• Mitochondrial function enhancers: Address energy deficits
• L-DOPA responsiveness: Patient-specific drug response prediction

Clinical Applications

Cell Replacement Therapy

iPSC-derived dopamine neurons represent a promising therapeutic approach for PD:

Allogeneic Transplantation

• BlueRock Therapeutics: Phase I trial with pluripotent stem cell-derived dopamine neurons
• CiRA Foundation (Kyoto): Clinical-grade iPSC banking for autologous transplantation
• International Stem Cell Initiative: Standardization of protocols

Autologous Transplantation

• Patient-derived iPSCs avoid immune rejection
• Requires 6-9 months for cell preparation
• Cost-prohibitive for widespread use

Clinical Trial Outcomes

Early-phase trials show:

• Survival of transplanted neurons in striatum
• Partial improvement in motor symptoms
• Need for immunosuppression in allogeneic transplants
• Continued research on optimal cell dosage and delivery

Challenges and Limitations

Technical Challenges

• Cell purity: Ensuring homogeneous dopaminergic neuron population
• Maturation: Achieving full functional maturity in vitro
• Survival: Improving graft survival after transplantation
• Integration: Proper axonal projection to striatum

Safety Concerns

• Tumorigenicity: Risk of undifferentiated iPSC contamination
• Overgrowth: Aberrant proliferation post-transplantation
• Dyskinesia: Risk of graft-induced dyskinesias
• Immunogenicity: Immune response to allogeneic cells

Manufacturing Challenges

• Scalability: Producing clinical-grade cells at scale
• Cost: Personalized cell therapy remains expensive
• Standardization: Establishing reproducible protocols
• Regulatory pathways: Navigating FDA/EMA approvals

Comparative Analysis

vs. Fetal Tissue Transplantation

vs. ESC-Derived Neurons

• iPSCs avoid ethical issues of embryonic stem cells
• Patient-specific disease modeling possible
• Autologous transplantation feasible
• Similar safety profile when purified

Future Directions

Research Priorities

• 3D organoid systems: Midbrain organoids for better modeling
• Gene editing: Correcting mutations in patient-derived iPSCs
• Biomarker development: Non-invasive monitoring of graft function
• Combination therapies: iPSC neurons with neurotrophic factors

Emerging Technologies

• Automated differentiation: Scalable manufacturing platforms
• Synthetic matrices: Optimized scaffolds for cell delivery
• Gene therapy enhancement: Combining cell therapy with neurotrophic support
• Patient stratification: Genetic markers predicting treatment response

Background

The study of Ipsc Derived Dopamine Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [NIH Stem Cell Information](https://stemcells.nih.gov/) - Federal stem cell research
• [The Michael J. Fox Foundation](https://www.michaeljfox.org/) - PD research and clinical trials](/clinical-trials)
• [BlueRock Therapeutics](https://www.bluerocktx.com/) - Cell therapy for Parkinson's disease

See Also

• [LC3 Protein](/wiki/proteins-lc3) — activates
• [Microglia](/wiki/cell-types-microglia) — activates
• [Microglia](/wiki/cell-types-microglia) — differentiates_to
• [Microglia](/wiki/cell-types-microglia) — implicated_in

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC-Derived Dopamine Neurons discovered through SciDEX knowledge graph analysis: